Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 4/20 | 0.42 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | TET3 | O43151 | 1/20 | 0.38 |
| ▸ | FBXL19 | Q6PCT2 | 1/20 | 0.38 |
| ▸ | CXXC5 | Q7LFL8 | 1/20 | 0.38 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25200465 | 0.92 | ALDH1A1 (0.43) | ALDH1A1NPC1KMT2AMEN1HPGD | |
| SCHEMBL22296232 | 0.92 | ALDH1A1 (0.43) | ALDH1A1NPC1KMT2AMEN1HPGD | |
| SCHEMBL1687958 | 0.88 | ALDH1A1 (0.41) | ALDH1A1NPC1KMT2AMEN1HPGD | |
| SCHEMBL15080935 | 0.88 | ALDH1A1 (0.41) | ALDH1A1NPC1KMT2AMEN1HPGD | |
| SCHEMBL15726987 | 0.88 | ALDH1A1 (0.41) | ALDH1A1NPC1KMT2AMEN1HPGD | |
| SCHEMBL21657795 | 0.84 | ALDH1A1 (0.42) | ALDH1A1NPC1KMT2AMEN1HPGD | |
| SCHEMBL22461349 | 0.84 | ALDH1A1 (0.41) | ALDH1A1NPC1KMT2AMEN1HPGD | |
| SCHEMBL25206318 | 0.83 | JAK3 (0.38) | ALDH1A1NPC1KMT2AMEN1HPGD | |
| SCHEMBL17099705 | 0.82 | TEAD1 (0.44) | KMT2ATEAD1TEAD3TET3FBXL19 | |
| SCHEMBL237862 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110981803-A | Anti-tumor compound and synthesis method and application thereof | 北京大学 | 2020-04-10 | — | — | CN | claimed |
| US-20250101241-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION | KJ CHEMICALS CORPORATION (JP) | 2025-03-27 | — | — | US | disclosed |
| EP-4435021-A1 | ACTIVE ENERGY RAY-CURABLE COMPOSITION | KJ Chemicals Corporation (JP) | 2024-09-25 | — | — | EP | disclosed |
| CN-118251428-A | Active energy ray-curable composition | 科巨希化学股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| US-20230391937-A1 | POLYMERIZABLE COMPOSITION, PRODUCT OF POLYMERIZATION OF SAME, AND MOLDED ARTICLE OBTAINED USING THESE | KJ CHEMICALS CORPORATION (JP) | 2023-12-07 | — | — | US | disclosed |
| US-20230364096-A1 | USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS | BEONE MEDICINES I GMBH (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230364096-A1 | USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS | BEONE MEDICINES I GMBH (CH) | 2023-11-16 | — | — | US | disclosed |
| US-20230346953-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-20230346953-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | UNITED STATES GOVERNMENT | 2023-11-02 | — | — | US | disclosed |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | CYTOSINLAB THERAPEUTICS CO., LTD. (CN) | 2023-10-26 | — | — | US | disclosed |
| US-7960396-B2 | Inhibitors of Bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20110039868-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100324050-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. A DELAWARE CORPORATION (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC | 2010-10-07 | — | — | US | disclosed |
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| US-7514444-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | PHARMACYCLICS, INC. (US) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022561-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885NPC1 4519/4885KMT2A 1124/4885 |
| US-20230391937-A1 | POLYMERIZABLE COMPOSITION, PRODUCT OF POLYMERIZATION OF SAME, AND MOLDED ARTICLE OBTAINED USING THESE | MTR, AHCY, MAT1A | ALDH1A1 1664/4885NPC1 4705/4885KMT2A 147/4885 |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885NPC1 4519/4885KMT2A 1124/4885 |
| US-20100324050-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885NPC1 4519/4885KMT2A 1124/4885 |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4461/4885NPC1 4551/4885KMT2A 1228/4885 |
| US-20100331350-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885NPC1 4519/4885KMT2A 1124/4885 |
| US-20230346953-A1 | SUBSTITUTED 3-AMINO-5-PHENYLBENZAMIDE COMPOUNDS AS COVALENT INHIBITORS OF ENHANCER ZESTE HOMOLOG 2 (EZH2) AND PROTEOLYSIS-TARGETING CHIMERIC DERIVATIVES THEREOF (PROTACS) THAT INDUCE DEGRADATION OF EZH2 | EZH2, BAZ2A, BAZ2B | ALDH1A1 2801/4885NPC1 4348/4885KMT2A 22/4885 |
| US-20110039868-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | ALDH1A1 4459/4885NPC1 4519/4885KMT2A 1124/4885 |
| US-20100254905-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | ABL1, BTK, ABL2 | ALDH1A1 4117/4885NPC1 3691/4885KMT2A 890/4885 |
| US-20230339936-A1 | COMPOUND HAVING KINASE INHIBITORY ACTIVITY | FLT3, ERBB2, ABL1 | ALDH1A1 2716/4885NPC1 4606/4885KMT2A 887/4885 |
| US-20080108636-A1 | compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are told | BTK, LCK, LYN | ALDH1A1 3930/4885NPC1 4210/4885KMT2A 994/4885 |
| US-20250101241-A1 | ACTIVE ENERGY RAY CURABLE COMPOSITION | PARP1, CAP1, XRN2 | ALDH1A1 1599/4885NPC1 4290/4885KMT2A 2181/4885 |
| US-20230364096-A1 | USE OF A COMBINATION COMPRISING A BTK INHIBITOR FOR TREATING CANCERS | BTK, LCK, LYN | ALDH1A1 3035/4885NPC1 4284/4885KMT2A 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.